To investigate the possibility that PPAR-γ activation may contribute to the maintenance of intestinal barrier, we utilized an in vitro system to evaluate whether PPAR-γ activation by the PPAR-γ agonist, pioglitazone, reverses CDI-driven tight junction breakage. The gene discussed is PPARG; the disease is clostridium difficile infection.